Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations (>=500 mg/dL). Omacor is a combination of the ethyl esters of icosapentaenoic (EPA) and docosahexaenoic (DHA) acids. It is the first drug derived from omega-3 PUFAs to be sold by prescription....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1221
Article Code: 1221b
Date: November 7, 2005
Volume: 47
Pages: 91-92
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1221
Article Code: 1221b
Date: November 7, 2005
Volume: 47
Pages: 91-92
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)